Clinicopathologic, surgical characteristics and survival outcomes of rectal gastrointestinal stromal tumors

Shen, Chaoyong; CHEN, H.; Yin, Rong; Yin, Yu; Han, Luyin; ZHANG, B.; CHEN, Z.; CHEN, J.

doi:10.4149/neo_2015_073

Cited by 9 publications

(7 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a case series in India, the main primary symptoms were pain (38.5%), bleeding (23.0%), and others (38.5%) (23). Shen et al described bleeding (28.9%), pain (17.8%), difficulty with defecation (11.1%), urinary complaints (6.7%), and other symptoms (11.1%) in 45 cases of rectal GIST (24). In a patient series in Japan the chief complaints were anal bleeding (30.3%), constipation (15.2%), anal discomfort (12.1%), palpitation of tumor (12.1%), abdominal pain (3.0%), and ischuria (3.0%) (22).…”

Section: Diagnosismentioning

confidence: 99%

“…In a patient series in Japan the chief complaints were anal bleeding (30.3%), constipation (15.2%), anal discomfort (12.1%), palpitation of tumor (12.1%), abdominal pain (3.0%), and ischuria (3.0%) (22). Table 1 summarizes the most common symptoms of rectal GIST, which are primarily bleeding and/or pain; urinary symptoms may occur more frequently than in GISTs at other sites (22)(23)(24)(25)(26).…”

Section: Diagnosismentioning

confidence: 99%

“…The KIT mutation genotypes in rectal GIST are not well known, but have been described in several studies, which are listed in Figure 1 (23)(24)(25)(26)58). As seen in GISTs developing at other sites, a large proportion (59-100%) of rectal GISTs carried exon 11 mutations.…”

Section: Im Therapy For Advanced/metastatic Gistmentioning

confidence: 99%

See 2 more Smart Citations

Management of rectal gastrointestinal stromal tumor

Kameyama¹,

Kanda²,

Tajima³

et al. 2018

Transl. Gastroenterol. Hepatol.

View full text Add to dashboard Cite

Gastrointestinal stromal tumor (GIST) is the most common mesenchymal neoplasm of the gastrointestinal tract. However, rectal GIST is rare, the incident rate of it is approximately 5% of all GISTs. Rectal GIST symptoms generally include bleeding and/or pain and occasionally, urinary symptoms. Immunohistochemical evaluation finds that most rectal GIST tumors are CD117 (KIT) positive, and are sometimes CD34, platelet-derived growth factor receptor alpha (PDGFRA), smooth muscle actin, S-100, or vimentin positive. The National Institutes of Health (NIH) classifies rectal GIST as very-low risk, low risk, intermediate risk, or high risk, and the frequencies have been estimated as 0-23.8% for very-low risk, 0-45% for low risk, 0-34% for intermediate risk, and 21-100% for high risk tumors. The first-line treatment for localized GIST is curative resection, but is difficult in rectal GIST because of anatomical characteristics such as the deep, narrow pelvis and proximity to the sphincter muscle or other organs. Several studies noted the efficacy of the minimally invasive surgery, such as trans-anal, trans-sacral, trans-vaginal resection, or laparoscopic resection. The appropriate surgical procedure should be selected depending on the case. Imatinib mesylate (IM) is indicated as first-line treatment of metastatic or unresectable GIST, and clinical outcomes are correlated with mutation genotype. However, the mutation genotypes in rectal GIST are not well known. In this review, as in other GISTs, a large proportion (59-100%) of rectal GISTs carry exon 11 mutations. Although curative resection is indicated for localized rectal GIST, a high rate of local recurrence is a problem. Multimodal therapy including perioperative IM may improve postoperative outcomes, contributing to anus-preserving surgery. Moreover, mutation analysis before IM treatment is important. This review summarizes current treatment strategies for rectal GIST.

show abstract

Section: Diagnosismentioning

confidence: 99%

Section: Diagnosismentioning

confidence: 99%

See 1 more Smart Citation

Management of rectal gastrointestinal stromal tumor

Kameyama¹,

Kanda²,

Tajima³

et al. 2018

Transl. Gastroenterol. Hepatol.

View full text Add to dashboard Cite

show abstract

“…V analyzovaném souboru byla systémová léčba podána u 73 % pa cientů. Multimodálním a centralizovaným přístupem bylo dosaženo kompletní remise u 80 % pa cientů s 5letým přežitím 90,6 %, což je délka odpovídající horní hranici délky přežívání v recentních zahraničních souborech pa cientů s GIST rekta (64,6-91 %) [24][25][26][27].…”

Section: Mitotický Indexunclassified

Gastrointestinal Stromal Tumours of the Rectum – Evaluating the National Registry Data with Respect to its Use in Clinical Practice

Svatoň¹,

Kala²,

Kysela³

et al. 2019

Klin Onkol

View full text Add to dashboard Cite

MU a FN Brno 2 Interní hematologická a onkologická klinika LF MU a FN Brno 3 Klinika radiologie a nukleární medicíny LF MU a FN Brno 4 Interní gastroenterologická klinika LF MU a FN Brno 5 Institut bio statistiky a analýz, LF MU, Brno Souhrn Východiska: Gastrointestinální stromální tumory (GIST) jsou vzácné maligní mezenchymální tumory s incidencí 1/ 100 000 obyvatel. Představují pouze 5 % gastrointestinálních nádorů. Nejčastěji je nalézáme v žaludku (60-70 %). Do rekta je jich situovaných < 5 %. V případě lokalizovaných, resekabilních tumorů je základem léčby chirurgická resekce. V závislosti na velikosti a lokalizaci tumoru v rektu volíme mezi lokální excizí, resekcí rekta s anastomózou nebo abdominoperitoneální amputací s trvalou stomií. Na rozdíl od karcinomů je metastazování GIST do lymfatických uzlin vzácné, a proto není z onkologického hlediska lymfadenektomie v podobě mezorektální excize vyžadována. Neoadjuvantní léčba s využitím inhibitorů tyrozinkináz (tyrosine kinase inhibitors-TKI) je doporučovaná např. u tumorů větších 5 cm, v případě prorůstaní do okolních orgánů nebo při infiltraci sfinkterů za účelem dosažení resekability a méně mutilujícího či kontinentního zákroku. V případě pozitivní resekční linie se můžeme pokusit o reresekci. Při CD117 pozitivitě lze zvážit adjuvantní léčbu TKI, kterou nasazujeme také po resekcích GIST středního a vysokého rizika maligního chování. U neresekabilních a metastazujících GIST je taktéž indikovaná léčba TKI. Materiál a metody: Analýza dat získaných z registru GIST k 1. 1. 2017, kdy do registru přispívalo 10 center z ČR. Výsledky: Z analyzovaných 1 095 pa cientů byla primární lokalizace GIST v rektu ve 45 případech (4,1 %). Průměrný věk pa cientů byl 60 let. V souboru bylo signifikantně více mužů (68,9 %; p = 0,0007) a symp tomatických pa cientů (62,2 %; p = 0,034). Operaci podstoupilo 82 % pa cientů. Z toho lokální excize byla provedena ve 37,8 %, resekce rekta s anastomózou ve 29,7 % a abdominoperineální amputace ve 29,7 %. V souboru bylo nejvíce tumorů velikosti 2-5 cm a necelá polovina vykazovala vysoké riziko maligního chování. Záznam o podání systémové léčby byl u 73 % pa cientů. Kompletní remise byla dosažena u 80 % pa cientů s GIST rekta. Medián přežití byl 11,3 roku a 5leté přežití je 90,6 %. Závěr: Navzdory úspěchům léčby TKI zůstává jedinou potenciálně kurativní metodou u GIST rekta chirurgická R0 resekce. Nejen vzhledem k nízké frekvenci výskytu těchto nádorů je správná dia gnostika a léčba náročná. Proto by měli být pa cienti s touto problematikou soustředěni do specializovaných center. Klíčová slova gastrointestinální stromální tumor (GIST)-rektum-terapie-resekce Tato práce byla podpořena grantem MZ ČR-RVO (FNBr, 65269705). This work was supported by grant MH CZ-RVO (FNBr, 65269705). Autoři deklarují, že v souvislosti s předmětem studie nemají žádné komerční zájmy. The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study. Redakční rada potvrzuje, že rukopis práce splnil ICMJE kritéria ...

show abstract

“…For instance, in [10] the IMAC is proposed, a new MAC protocol that exploits time synchronization achieved via low-frequency radio waves to minimize power consumption of so called "Low Power Listening" [11]. Similarly, a low-power commercial device is used in [12] to perform time synchronization in a wireless sensor network.…”

Section: The Proposed Approachmentioning

confidence: 99%

Inexpensive SDR-based longwave radio controlled clock for time dissemination in industrial wireless sensor networks

Depari¹,

Flammini²,

Lavarini³

et al. 2015

2015 IEEE International Conference on Automation Science and Engineering (CASE)

View full text Add to dashboard Cite

LF and VLF (very low frequency) wireless links have long been used to perform time and frequency dissemination. Indeed, several standard time services exploiting (V)LF signaling are continuously transmitting in many locations around the world, despite they face the competition from the Global Positioning System (GPS), which offers an higher clock synchronization accuracy. In fact, (V)LF signaling ensures an overall accuracy adequate for most of civil and industrial applications, offering indoor reception capability at lower cost and lower power than GPS systems. This work describes a full digital implementation, exploiting the Software Defined Radio paradigm, of a LF receiver, capable to simultaneously perform both the amplitude and phase demodulation of the incoming time reference signal, and of a servo-clock for the time synchronization of wireless sensor network nodes. Despite the DCF77 standard has been considered for the real world implementation, the SDR approach allows to easily migrate to other similar standards worldwide available. The increased system complexity is mitigated by the improved flexibility; in addition, the computational core of the SDR can be sized to be shared among several wireless technologies simultaneously handled. The realworld prototype is implemented by means of a single inexpensive digital signal controller (a member of the dsPIC33 family from Microchip), requiring very few external components. Several experiments have been carried out in a controlled environment, confirming an overall sub-millisecond time synchronization accuracy.

show abstract

Clinicopathologic, surgical characteristics and survival outcomes of rectal gastrointestinal stromal tumors

Cited by 9 publications

References 22 publications

Management of rectal gastrointestinal stromal tumor

Management of rectal gastrointestinal stromal tumor

Gastrointestinal Stromal Tumours of the Rectum – Evaluating the National Registry Data with Respect to its Use in Clinical Practice

Inexpensive SDR-based longwave radio controlled clock for time dissemination in industrial wireless sensor networks

Contact Info

Product

Resources

About